CTRI/2024/07/071253尚未招募2 期
A randomized, double blind, placebo-controlled, parallel arm clinical trial of De-Stress and Snooze Gummies in reducing stress, insomnia disorder, associated symptoms and oveall quality of life. - NI
Herbolab India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male and female participants aged 21-50 years both inclusive 2.Suffering from self-reported mild to moderate stress on the PSS scale score less than or equal to 26 3.Participants willing to participate in clinical trials and who have read understood and signed the informed consent form 4.Participants diagnosed with insomnia disorder based on the Diagnostic and Statistical Manual of Mental Disorders text revision DSM-V-TR 5.Insomnia Severity Index more than 7 and less than 21 i.e. mild to moderate 6.Participants with a diagnosis of mild or moderate depression patient’s health questionnaire PHQ-9 score of less than or equal to 14 7.Participants with a diagnosis of mild or moderate generalized anxiety disorder GAD -7 questionnaire score of less than or equal to 10.
排除标准
- •1.Difficulty sleeping due to a medical condition
- •2.History of a neurological disorder
- •3.History of bipolar disorder psychotic disorder or posttraumatic stress disorder or current psychiatric disorder that requires medication
- •4.On-going depression and generalized anxiety disorder diagnosis on PHQ 9 score greater than or equal to 15 and GAD-7 score greater than or equal to 11 scales
- •5.History of substance abuse or dependence
- •6.History or current evidence of a clinically significant cardiovascular disorder at pre-study visit
- •7.Taking certain prohibited medications
- •8.Consumption of greater than 10 cigarettes a day
- •9.Participants who consume greater than or equal to 120 mg/day of caffeine and are unwilling to restrict their intake throughout the study
- •10.Current evidence or history of malignancy less than or equal to 5 years prior to signing informed consent
- •11.Participants currently using any nutraceutical, allopathic, or ayurvedic supplement for stress or insomnia management
- •12.Known hypersensitivity to any ingredients of product
- •13.Pregnant or lactating women, as well as women of childbearing potential who are not using contraception or intending to conceive during the study
- •14.Other conditions, which in the opinion of the investigators, makes the participant unsuitable for enrolment or could interfere with his her participation in and completion of the protocol.
研究者
相似试验
进行中(未招募)
不适用
An international study assessing the efficacy of a new drug (S 066913) in paroxysmal atrial fibrillatioParoxysmal Atrial FibrillationEUCTR2014-002333-63-SKInstitut de Recherches Internationales Servier160
进行中(未招募)
1 期
An international study assessing the efficacy of a new drug (S 066913) in paroxysmal atrial fibrillatioMedDRA version: 18.0Level: LLTClassification code 10034039Term: Paroxysmal atrial fibrillationSystem Organ Class: 100000004849Paroxysmal Atrial FibrillationEUCTR2014-002333-63-CZInstitut de Recherches Internationales Servier160
已完成
2 期
A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in patients with paroxysmal atrial fibrillation. Double-blind, International study AssessinG efficacy of S066913 in paRoxysmal Atrial Fibrillation -IKur inhibitor (DIAGRAF - IKUR)paroxysmal atrial fibrillationNL-OMON41862Institut de Recherches Internationales Servier I.R.I.S34
已完成
2 期
A randomized, double blind, placebo-controlled, parallel group, multicentre, phase 2a study to assess target engagement, safety and tolerability of AZD4831 in patients with Heart Failure with preserved Ejection Fraction (HFpEF).10019280Heart FailureHFpEFNL-OMON49300Astra Zeneca16
尚未招募
2 期
A clinical study of De-Stress & Chill Gummies in reducing stressCTRI/2024/07/071254Herbolab India Pvt Ltd
